FDA Grants Orphan Drug Designation to AGMB-447 for Idiopathic Pulmonary Fibrosis
Currently, the drug is being evaluated in a phase 1 clinical trial to determine the safety and efficacy in patients.
Source: pharmacytimes.com
Philippe Wiesel News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Philippe Wiesel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Philippe Wiesel Today - Breaking & Trending Today
Novel Antifibrotic Gets Orphan Drug Status for Idiopathic Pulmonary Fibrosis
The FDA has granted Orphan Drug designation to AGMB-447 for the treatment of idiopathic pulmonary fibrosis.
Source: empr.com
Investigational Antifibrotic Therapy Fast Tracked for Fibrostenosing Crohn Disease
The Food and Drug Administration has granted Fast Track designation to AGMB-129 for the treatment of symptomatic fibrostenosing Crohn disease.
Source: empr.com
Agomab Therapeutics NV: Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn's Disease
-- All dosing regimens were well-tolerated across the Phase 1 clinical study -- -- High local exposure to AGMB-129 in the ileum -- -- No clinically relevant systemic exposure to AGMB-129, confirming
Source: finanznachrichten.de
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators -- Company expands leadership team with CMO Philippe Wiesel, CBO Paul van der Horst and CFO Tolga Hassan -- AgomAb Therapeutics N.V. announced today the closing of a $74 million Series B financing round led by Redmile Group, with participation from Cormorant Asset Management. All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures. The proceeds of the Series B will be...
Source: finanznachrichten.de